Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Lenexa, Kansas 66219


This non-randomized, open-label study will evaluate the interaction of RO5190591(danoprevir)/ritonavir with and without ketoconazole and the safety and tolerability in healthy volunteers. Participants will be administered repeated daily doses of ketoconazole alone, RO5190591/ritonavir, and RO5190591/ritonavir plus ketoconazole. The anticipated time on study treatment is 25 days.


Inclusion Criteria: - Adult healthy volunteers, aged 18-64 years, inclusively - Weight >/=50.0 kg - Body Mass Index (BMI) 18.0-32.0 kg/m2 - Ability and willingness to abstain from alcohol, xanthine-containing beverages or food (coffee, tea, cola, chocolate, "energy drinks") from 48 hours prior to entry in the clinical study center until discharge - Ability and willingness to abstain from grapefruit or grapefruit juice, star fruit, and Seville oranges from 7 days prior to entry in the clinical study center until discharge - Medical history without major recent or ongoing pathology Exclusion Criteria: - Pregnant or lactating women and male partners of women who are pregnant or lactating - Sustained supine systolic blood pressure >140 or <90 mmHG and supine diastolic blood pressure >90 or <50 mmHG at Screening or Day -1 - Resting heart rate >100 or <45 beats per minute at Screening or Day -1 - Any history of clinically significant cardiovascular or cerebrovascular disease - Positive drug test result at screening or each admission - Donation or loss of blood over 450 ml (1 pint) within 60 days prior to screening

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

A Study of RO5190591 (Danoprevir) in Healthy Volunteers

Official Title:

A Two-Way Interaction Study Between RO5190591/RTV and Ketoconazole in Healthy Subjects

Overall Status:


Study Phase:

Phase 1



Minimum Age:

18 Years

Maximum Age:

64 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Hoffmann-La Roche

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Endpoint Classification: Pharmacokinetics Study, I

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Clinical Trials
Study Director
Hoffmann-La Roche

Study Dates

Start Date:July 2010
Completion Date:August 2010
Completion Type:Actual
Primary Completion Date:August 2010
Primary Completion Type:Actual
Verification Date:August 2016
Last Changed Date:August 26, 2016
First Received Date:July 15, 2010

Study Outcomes

Outcome Type:Primary Outcome
Measure:To investigate the interaction between RO5190591/ritonavir and ketoconazole
Time Frame:Day 40
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:To assess the safety and tolerability of multiple doses of RO5190591/ritonavir without and with ketoconazole
Time Frame:Day 40
Safety Issues:False

Study Interventions

Intervention Type:Drug
Description:Repeated daily doses
Arm Name:1
Intervention Type:Drug
Description:Repeated daily doses
Arm Name:1
Intervention Type:Drug
Description:Repeated daily doses
Arm Name:1

Study Arms

Study Arm Type:Experimental
Arm Name:1

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Hoffmann-La Roche

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.